ZeroDailyGet it on Google Play

FDA slams brakes on promising lung cancer drug, demands proof patients actually live longer

Original headline: The FDA declined to approve one of biotech’s most closely watched cancer drugs — marketwatch.com

More in Technology finance news

The U.S. Food and Drug Administration rejected Summit Therapeutics' application for a closely watched new lung cancer drug. The regulator issued a formal notice stating the company must demonstrate the treatment improves overall survival for patients, a higher bar than the initial data provided. This drug had been a focal point for investors and oncologists hoping for a new treatment option.

For the biotech industry and its investors, this is a significant clinical and regulatory setback. It highlights the FDA's increasing scrutiny on proving real patient benefit, not just tumor shrinkage. The decision will delay the drug's potential availability and forces Summit back to the drawing board to run longer, more conclusive trials, underscoring the high stakes of bringing a new cancer therapy to market.

Read the original at marketwatch.com

Satirical commentary on real tech news, summarised with AI. Read the original source for the facts. How ZeroDaily works

Open in the appGet it on Google Play

More stories

Add ZeroDaily on Google